Everest Medicines

View the org chart displaying its 15 main executives

Most searched biographies at Everest Medicines

• Yongqing Luo, Executive Director and Chief Executive Officer
• Wei Fu, Chairman of the Board
• Shidong Jiang, Independent Non-Executive Directors

Popular executive movements at Everest Medicines

• Sandra Zeng has joined the company as Chief Medical Officer  (posted on March 18 2024).
• Rico Liang has joined the company as Chief Product Officer  (posted on March 18 2024).
• Lan Kang, Director, has left the company  (posted on January 14 2024).

Click here to view some more movements at Everest Medicines

Create your alert
to follow the executive moves at Everest Medicines.

Everest Medicines has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Everest Medicines

• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 – Everest Medicines
• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 – Everest Medicines
• Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer – Everest Medicines
• Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients – Everest Medicines
• Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® – Everest Medicines
• Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer – Everest Medicines
• Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients – Everest Medicines
• Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® – Everest Medicines
• Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 – Everest Medicines
• Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau – Everest Medicines
• View more press releases Close

Social media about Everest Medicines

• Everest Medicines on Wikipedia, Google News & Yahoo Finance
• Everest Medicines on LinkedIn, Twitter & YouTube

Contact by email its executives including Yifan Li

Call Everest Medicines at +1 203...

View the org chart

Register to receive your alert

Report an error